Pomavid®; Our dedication to shaping hope

07 June, 2024

NanoAlvand as leading manufacturer of anti-cancer products, is proud to announce the launch of Pomavid®, a high-quality version of pomalidomide. Pomavid® is a new generation medication for the treatment of multiple myeloma, a type of blood cancer. Pomavid® is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen. NanoAlvand has leveraged its state-of-the-art manufacturing facilities and cutting-edge technology to produce Pomavid®, ensuring the highest quality standards.

Our advanced manufacturing capabilities and unwavering dedication to quality have enabled us to deliver a highly effective and affordable alternative to the branded product. Pomavid® will be available in 1 mg, 2 mg, 3 mg, and 4 mg hard capsule strengths, providing healthcare professionals with a range of dosing options to tailor treatment to individual patient needs.

Super User

Apply for a Job Position

Curious about job opportunities?

© NanoAlvand. All rights reserved. Powered by ِDGN.